Obi Pharma Inc. has received FDA clearance for its IND application to conduct a phase I/II study of OBI-992, a novel antibody-drug conjugate (ADC) cancer therapy targeting TROP2. The trial will open shortly and aims to enroll patients with advanced solid tumors, including non-small-cell lung cancer, small-cell lung cancer and gastric cancer, although several other cancers are also potential targets.
Bispecific antibodies acting through CEACAM5/CD3 targeting have limited efficacy due to dose-limiting toxicities, insufficient T-cell activation and formation of anti-drug antibodies (ADAs). Researchers from Novimmune SA and Lampkap Bio Alpha AG have published data on a CEACM5/CD3 bispecific antibody, NILK-2301, which is formed by a heavy chain plus two different light chains (kappa and lambda body) as a potential immunotherapeutic with better efficacy and lower potential for ADA formation.
Chimeric antigen receptor (CAR) therapies targeted against CD19 have been widely used for the treatment of B-cell malignancies. However, the down-regulation of CD19 can lead to relapse, and autologous CAR T therapies have limitations that need to be addressed.
Researchers from Mbrace Therapeutics Inc. presented the discovery and preclinical evaluation of MBRC-101, a novel antibody-drug conjugate (ADC) targeting the membrane-associated tyrosine kinase receptor EphA5, being developed for the treatment of cancer.
Biocytogen Pharmaceuticals Co. Ltd. and Ctm Biotech Co. Ltd. have reported progress in the development of a trispecific T-cell engager for an intracellular target.
Immunoscape Pte Ltd. and Mink Therapeutics Inc. have entered into a collaboration agreement to discover and develop next-generation T-cell receptor (TCR) therapies against novel targets in solid tumors.
Replay Holdings LLC has entered into an exclusive, worldwide license agreement with the National Institutes of Health (NIH) for intellectual property related to a library of T-cell receptors (TCRs) directed against multiple cancer neoantigens.
Inxmed Co. Ltd. has licensed Escugen’s Ezwi-Fit linker-payload platform for use in the development of next-generation tumor-associated antigen (TAA)-targeting antibody-drug conjugates (ADCs).
Gilead Sciences Inc. has signed an agreement with Compugen Ltd. to exclusively license Compugen’s preclinical antibody program against IL-18 binding protein, including the COM-503 drug candidate. COM-503 is a high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby inhibiting cancer growth.
RSS
